Roche Reports Phase 3 extension Data for Inclisiran in Coronary artery disease

Roche today announced Phase 3 extension results for inclisiran in patients with coronary artery disease. The study demonstrated that inclisiran reduces hospitalization rates compared to standard of care or placebo. These results provide important insights into the treatment of coronary artery disease and support the continued development of inclisiran in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.